References
- Gotlib J. How I treat atypical chronic myeloid leukemia. Blood. 2017;129(7):838–845. doi:10.1182/blood-2016-08-693630
- Fontana D, Gambacorti-Passerini C, Piazza R. Molecular pathogenesis of BCR-ABL-Negative atypical chronic myeloid leukemia. Front Oncol. 2021;11:756348. doi:10.3389/fonc.2021.756348
- Schwartz LC, Mascarenhas J. Current and evolving understanding of atypical chronic myeloid leukemia. Blood Rev. 2019;33:74–81. doi:10.1016/j.blre.2018.07.004
- Patel KP, Newberry KJ, Luthra R, et al. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood. 2015;126(6):790–797. doi:10.1182/blood-2015-03-633404
- Cassinat B, Verger E, Maslah N, et al. CCND2 mutations are infrequent events in BCR-ABL1 negative myeloproliferative neoplasm patients. Haematologica. 2021;106(3):863–864. doi:10.3324/haematol.2020.252643
- Khanna V, Eide CA, Tognon CE, et al. Recurrent cyclin D2 mutations in myeloid neoplasms. Leukemia. 2017;31(9):2005–2008. doi:10.1038/leu.2017.195
- Eisfeld AK, Kohlschmidt J, Schwind S, et al. Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia. Leukemia. 2017;31(6):1278–1285. doi:10.1038/leu.2016.332
- Faber ZJ, Chen X, Gedman AL, et al. The genomic landscape of core-binding factor acute myeloid leukemias. Nat Genet. 2016;48(12):1551–1556. doi:10.1038/ng.3709